{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:40:09Z","timestamp":1794746409195,"version":"4.9.1"},"reference-count":210,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["7790008056"],"award-info":[{"award-number":["7790008056"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["K2023010"],"award-info":[{"award-number":["K2023010"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["ZDLYG04"],"award-info":[{"award-number":["ZDLYG04"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Project of Jiangsu Provincial Health Commission","award":["7790008056"],"award-info":[{"award-number":["7790008056"]}],"id":[{"id":"https:\/\/ror.org\/03eqskn19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Project of Jiangsu Provincial Health Commission","award":["K2023010"],"award-info":[{"award-number":["K2023010"]}],"id":[{"id":"https:\/\/ror.org\/03eqskn19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Project of Jiangsu Provincial Health Commission","award":["ZDLYG04"],"award-info":[{"award-number":["ZDLYG04"]}],"id":[{"id":"https:\/\/ror.org\/03eqskn19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds","award":["7790008056"],"award-info":[{"award-number":["7790008056"]}]},{"name":"Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds","award":["K2023010"],"award-info":[{"award-number":["K2023010"]}]},{"name":"Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds","award":["ZDLYG04"],"award-info":[{"award-number":["ZDLYG04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Liver fibrosis is a progressive scarring process primarily caused by chronic inflammation and injury, often closely associated with viral hepatitis, alcoholic liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), drug-induced liver injury, and autoimmune liver disease (AILD). Currently, there are very few clinical antifibrotic drugs available, and effective targeted therapy is lacking. Recently, emerging antifibrotic drugs and immunomodulators have shown promising results in animal studies, and some have entered clinical research phases. This review aims to systematically review the molecular mechanisms underlying liver fibrosis, focusing on advancements in drug treatments for hepatic fibrosis. Furthermore, since liver fibrosis is a progression or endpoint of many diseases, it is crucial to address the etiological treatment and secondary prevention for liver fibrosis. We will also review the pharmacological treatments available for common hepatitis leading to liver fibrosis.<\/jats:p>","DOI":"10.3390\/ph17121724","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:44:33Z","timestamp":1734677073000},"page":"1724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances"],"prefix":"10.3390","volume":"17","author":[{"given":"Liangtao","family":"Zhao","sequence":"first","affiliation":[{"name":"Hepato-Pancreato-Biliary Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolan","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Medicine, Southeast University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-7535","authenticated-orcid":false,"given":"Zhangjun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hepato-Pancreato-Biliary Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3748\/wjg.v28.i16.1718","article-title":"Viral hepatitis: A global burden needs future directions for the management","volume":"28","author":"Verma","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1148\/radiol.13122482","article-title":"Liver fibrosis: Histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging","volume":"269","author":"Feier","year":"2013","journal-title":"Radiology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: Trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3345\/cep.2022.00367","article-title":"Liver fibrosis in children: A comprehensive review of mechanisms, diagnosis, and therapy","volume":"66","author":"Ozdogan","year":"2023","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s11033-020-05290-0","article-title":"Neovascularization is a key feature of liver fibrosis progression: Anti-angiogenesis as an innovative way of liver fibrosis treatment","volume":"47","author":"Zadorozhna","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Singh, S., Sharma, N., Shukla, S., Behl, T., Gupta, S., Anwer, M.K., Vargas-De-La-Cruz, C., Bungau, S.G., and Brisc, C. (2023). Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics. Molecules, 28.","DOI":"10.3390\/molecules28062811"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1111\/febs.15693","article-title":"Metabolic requirements of pulmonary fibrosis: Role of fibroblast metabolism","volume":"288","author":"Hamanaka","year":"2021","journal-title":"FEBS J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Khanam, A., Saleeb, P.G., and Kottilil, S. (2021). Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. Cells, 10.","DOI":"10.3390\/cells10051097"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kataoka, S., Umemura, A., Okuda, K., Taketani, H., Seko, Y., Nishikawa, T., Yamaguchi, K., Moriguchi, M., Kanbara, Y., and Arbiser, J.L. (2021). Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-beta1\/SMAD Signaling and Autophagy in Hepatic Stellate Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413354"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","article-title":"New clinical and pathophysiological perspectives defining the trajectory of cirrhosis","volume":"75","author":"Jalan","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"124381","DOI":"10.1016\/j.ijpharm.2024.124381","article-title":"Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives","volume":"660","author":"Unagolla","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1080\/21655979.2022.2047403","article-title":"Trimetazidine inhibits liver fibrosis and hepatic stellate cell proliferation and blocks transforming growth factor-beta (TGFbeta)\/Smad signaling in vitro and in vivo","volume":"13","author":"Ding","year":"2022","journal-title":"Bioengineered"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/liv.14940","article-title":"Hepatic macrophages: Key players in the development and progression of liver fibrosis","volume":"41","author":"Cheng","year":"2021","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Binatti, E., Gerussi, A., Barisani, D., and Invernizzi, P. (2022). The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126649"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bao, Y.L., Wang, L., Pan, H.T., Zhang, T.R., Chen, Y.H., Xu, S.J., Mao, X.L., and Li, S.W. (2021). Animal and Organoid Models of Liver Fibrosis. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.666138"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"G110","DOI":"10.1152\/ajpgi.00412.2010","article-title":"Hepatic stellate cells require a stiff environment for myofibroblastic differentiation","volume":"301","author":"Olsen","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1080\/07853890.2022.2132418","article-title":"The role of hepatic microenvironment in hepatic fibrosis development","volume":"54","author":"Meng","year":"2022","journal-title":"Ann. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Park, H., Yoon, E.L., Kim, M., Cho, S., Kim, J.H., Jun, D.W., and Nah, E.H. (2022). Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061474"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e385823","DOI":"10.1590\/acb385823","article-title":"Saffron reduces the liver fibrosis in mice by inhibiting the JAK\/STAT3 pathway","volume":"38","author":"Huang","year":"2023","journal-title":"Acta Cir. Bras."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10735-020-09868-7","article-title":"HOXB13 expression is correlated with hepatic inflammatory activity of patients with hepatic fibrosis","volume":"51","author":"Zuo","year":"2020","journal-title":"J. Mol. Histol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Aleknavi\u010di\u016bt\u0117-Valien\u0117, G., and Banys, V. (2022). Clinical importance of laboratory biomarkers in liver fibrosis. Biochem. Med., 32.","DOI":"10.11613\/BM.2022.030501"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.35248\/2167-0889.19.8.236","article-title":"Liver Fibrosis Conventional and Molecular Imaging Diagnosis Update","volume":"8","author":"Li","year":"2019","journal-title":"J. Liver"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1038\/s41467-024-52308-3","article-title":"A FAP\u03b1-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cld.2008.07.012","article-title":"Genetic determinants in hepatic fibrosis: From experimental models to fibrogenic gene signatures in humans","volume":"12","author":"Weber","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1074\/jbc.TM118.002812","article-title":"Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease","volume":"294","author":"Ito","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1172\/JCI117617","article-title":"Coexpression of the collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis","volume":"94","author":"Masuda","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0165-2478(94)90072-8","article-title":"An endogenous lectin, galectin-3 (epsilon BP\/Mac-2), potentiates IL-1 production by human monocytes","volume":"42","author":"Jeng","year":"1994","journal-title":"Immunol. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1021\/jf402082g","article-title":"Peroxisome proliferator-activated receptor-gamma activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling","volume":"61","author":"Hsu","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/00365520802530861","article-title":"Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice","volume":"44","author":"Nan","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3350\/cmh.2022.0237","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrneph.2016.54","article-title":"Developmental signalling pathways in renal fibrosis: The roles of Notch, Wnt and Hedgehog","volume":"12","author":"Edeling","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","article-title":"\u03b2-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis","volume":"148","author":"Monga","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1073\/pnas.0404875101","article-title":"A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]","volume":"101","author":"Emami","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","article-title":"Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP\/beta-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial","volume":"23","author":"Kimura","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1021\/acsmedchemlett.0c00679","article-title":"Discovery of Selective Transforming Growth Factor beta Type II Receptor Inhibitors as Antifibrosis Agents","volume":"12","author":"Miwa","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1164\/rccm.200405-612OC","article-title":"Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor","volume":"171","author":"Bonniaud","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1667\/RADE-23-00202.1","article-title":"A Novel TGFbeta Receptor Inhibitor, IPW-5371, Prevents Diet-induced Hepatic Steatosis and Insulin Resistance in Irradiated Mice","volume":"202","author":"Szalanczy","year":"2024","journal-title":"Radiat. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123068","DOI":"10.1016\/j.ijpharm.2023.123068","article-title":"Oral targeted delivery of Imatinib by pH responsive copolymer modulates liver fibrosis in the mice model","volume":"641","author":"Siapoush","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2017.09.035","article-title":"Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis","volume":"266","author":"Shalaby","year":"2017","journal-title":"J. Control Release"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Reichert, D., Adolph, L., Kohler, J.P., Buschmann, T., Luedde, T., Haussinger, D., and Kordes, C. (2021). Improved Recovery from Liver Fibrosis by Crenolanib. Cells, 10.","DOI":"10.3390\/cells10040804"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Maggisano, M., Mondini, L., Chernovsky, M., Confalonieri, P., Salton, F., Reccardini, N., Kodric, M., Geri, P., Confalonieri, M., and Hughes, M. (2024). Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease. Pharmaceuticals, 17.","DOI":"10.3390\/ph17091147"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13071-019-3539-z","article-title":"rSjp40 inhibits activated hepatic stellate cells by promoting nuclear translocation of YB1 and inducing BMP-7\/Smad1\/5\/8 pathway","volume":"12","author":"Chen","year":"2019","journal-title":"Parasit. Vectors"},{"key":"ref_55","first-page":"771","article-title":"Nanostructure-based therapies for liver fibrosis","volume":"71","author":"Mitrea","year":"2020","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Qiu, C., Liu, Y., Huang, S., Ning, B., He, S., and Zhong, L. (2022). Rab31 promotes activation of hepatic stellate cells by accelerating TGF-beta receptor II complex endocytosis. Int. J. Biochem. Cell Biol., 144.","DOI":"10.1016\/j.biocel.2022.106170"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zheng, Y., Yang, Y., Liu, K., Wu, J., Gao, P., and Zhang, C. (2023). Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1133297"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Di Fazio, P., Mielke, S., Bohm, I.T., Buchholz, M., Matrood, S., Schuppan, D., and Wissniowski, T. (2023). Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation. BMJ Open Gastroenterol., 10.","DOI":"10.1136\/bmjgast-2023-001148"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.actbio.2023.06.032","article-title":"CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis","volume":"168","author":"Li","year":"2023","journal-title":"Acta Biomater."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2303710","DOI":"10.1002\/adhm.202303710","article-title":"Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis","volume":"13","author":"Wang","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dai, W., Qin, Q., Li, Z., Lin, L., Li, R., Fang, Z., Han, Y., Mu, W., Ren, L., and Liu, T. (2021). Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-beta Pathway and Inhibiting Oxidative Stress. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.763864"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"106783","DOI":"10.1016\/j.ejps.2024.106783","article-title":"Hyaluronic acid modified extracellular vesicles targeting hepatic stellate cells to attenuate hepatic fibrosis","volume":"198","author":"Yu","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.3389\/jpps.2023.11808","article-title":"Current investigations for liver fibrosis treatment: Between repurposing the FDA-approved drugs and the other emerging approaches","volume":"26","author":"Mohammed","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wei, Q., Gan, C., Sun, M., Xie, Y., Liu, H., Xue, T., Deng, C., Mo, C., and Ye, T. (2024). BRD4: An effective target for organ fibrosis. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00641-6"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Middleton, S.A., Rajpal, N., Cutler, L., Mander, P., Rioja, I., Prinjha, R.K., Rajpal, D., Agarwal, P., and Kumar, V. (2018). BET Inhibition Improves NASH and Liver Fibrosis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-35653-4"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1080\/21655979.2022.2066756","article-title":"Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis","volume":"13","author":"Fu","year":"2022","journal-title":"Bioengineered"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jhep.2005.02.034","article-title":"Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice","volume":"43","author":"Yang","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients with Primary Biliary Cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_78","first-page":"e67083","article-title":"Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review","volume":"16","author":"Dhande","year":"2024","journal-title":"Cureus"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Liu, L., Wang, B., Ma, Y., Sun, K., Wang, P., Li, M., Dong, J., Qin, M., Li, M., and Wei, C. (2024). A review of Phyllanthus urinaria L. in the treatment of liver disease: Viral hepatitis, liver fibrosis\/cirrhosis and hepatocellular carcinoma. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1443667"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9667","DOI":"10.1111\/jcmm.15498","article-title":"Isoliquiritigenin ameliorates caerulein-induced chronic pancreatitis by inhibiting the activation of PSCs and pancreatic infiltration of macrophages","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lee, H.J. (2022). Therapeutic Potential of the Combination of Pentoxifylline and Vitamin-E in Inflammatory Bowel Disease: Inhibition of Intestinal Fibrosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164713"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1021\/acsami.9b21214","article-title":"Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA\/miRNA Combination Cancer Therapy","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2018.05.032","article-title":"Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis","volume":"283","author":"Qiao","year":"2018","journal-title":"J. Control Release"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2040622320942042","DOI":"10.1177\/2040622320942042","article-title":"GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-beta1 inhibition","volume":"11","author":"Bestion","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_87","first-page":"66664","article-title":"Role of Macrophages in Liver Fibrosis","volume":"78","author":"Sun","year":"2024","journal-title":"Acta Med. Okayama"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: From mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/SAP.0000000000001955","article-title":"Targeting Fibrotic Signaling: A Review of Current Literature and Identification of Future Therapeutic Targets to Improve Wound Healing","volume":"83","author":"Hetzler","year":"2019","journal-title":"Ann. Plast. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Cagnoni","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.ajpath.2021.08.004","article-title":"Inhibition of Hepatic Stellate Cell Activation Suppresses Tumorigenicity of Hepatocellular Carcinoma in Mice","volume":"191","author":"Kang","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s13197-024-06002-3","article-title":"Inhibition of hepatic stellate cell activation by nutraceuticals: An emphasis on mechanisms of action","volume":"61","author":"Sekar","year":"2024","journal-title":"J. Food Sci. Technol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bbalip.2019.02.004","article-title":"Hepatic stellate cell activation: A source for bioactive lipids","volume":"1864","author":"Shmarakov","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Li, J., Yao, S., Zimny, S., Koob, D., Jin, H., Wimmer, R., Denk, G., Tuo, B., and Hohenester, S. (2024). The acidic microenvironment in the perisinusoidal space critically determines bile salt-induced activation of hepatic stellate cells. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-07192-4"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"111474","DOI":"10.1016\/j.intimp.2023.111474","article-title":"Inhibition of Sirt3 activates the cGAS-STING pathway to aggravate hepatocyte damage in hepatic ischemia-reperfusion injury mice","volume":"128","author":"Kong","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_96","first-page":"56","article-title":"Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF-\u03baB pathways","volume":"10","author":"Zhang","year":"2023","journal-title":"Mil. Med. Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tan, S., Lu, X., Chen, W., Pan, B., Kong, G., and Wei, L. (2024). Analysis and experimental validation of IL-17 pathway and key genes as central roles associated with inflammation in hepatic ischemia-reperfusion injury. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-57139-2"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12939-024-02153-z","article-title":"High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: A population-based study in Australia","volume":"23","author":"Valery","year":"2024","journal-title":"Int. J. Equity Health"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zazueta, A., Valenzuela-Perez, L., Ortiz-Lopez, N., Pinto-Leon, A., Torres, V., Guinez, D., Aliaga, N., Merino, P., Sandoval, A., and Covarrubias, N. (2024). Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084387"},{"key":"ref_101","first-page":"S41","article-title":"Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Noureddin","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D.M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., and Mingarelli, E. (2017). Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-11744-6"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jgh.15746","article-title":"The microbial metabolome in metabolic-associated fatty liver disease","volume":"37","author":"Li","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Elinav","year":"2012","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jcmgh.2022.06.007","article-title":"Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis","volume":"14","author":"Kaufmann","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.32776","article-title":"Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis","volume":"77","author":"Knorr","year":"2023","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8962458","DOI":"10.1155\/2017\/8962458","article-title":"Deficiency of the Purinergic Receptor 2X(7) Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome","volume":"2017","author":"Menini","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Asimakopoulou, A., Engel, K.M., Gassler, N., Bracht, T., Sitek, B., Buhl, E.M., Kalampoka, S., Pinoe-Schmidt, M., van Helden, J., and Schiller, J. (2020). Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation. Cells, 9.","DOI":"10.3390\/cells9061346"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","article-title":"Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis","volume":"70","author":"Koh","year":"2021","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1038\/s41467-024-48954-2","article-title":"Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2alpha","volume":"15","author":"Xia","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1136\/gutjnl-2021-325013","article-title":"NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression","volume":"71","author":"Latif","year":"2022","journal-title":"Gut"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Vidal-Cevallos, P., Sorroza-Martinez, A.P., Chavez-Tapia, N.C., Uribe, M., Montalvo-Jave, E.E., and Nuno-Lambarri, N. (2024). The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084397"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2169\/internalmedicine.0277-22","article-title":"Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease","volume":"62","author":"Imamura","year":"2023","journal-title":"Intern. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.23167","article-title":"Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis","volume":"50","author":"Witek","year":"2009","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/ijo.2016.74","article-title":"Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-\/-.Leiden mice","volume":"40","author":"Morrison","year":"2016","journal-title":"Int. J. Obes."},{"key":"ref_120","first-page":"1148","article-title":"Gasdermin D Inhibitor Necrosulfonamide Alleviates Lipopolysaccharide\/D-galactosamine-induced Acute Liver Failure in Mice","volume":"10","author":"Wu","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"123294","DOI":"10.1172\/jci.insight.123294","article-title":"ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model","volume":"5","author":"Geisler","year":"2020","journal-title":"JCI Insight"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2020.11.009","article-title":"NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice","volume":"534","author":"Wang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s11695-020-04571-8","article-title":"Sleeve Gastroplasty Combined with the NLRP3 Inflammasome Inhibitor CY-09 Reduces Body Weight, Improves Insulin Resistance and Alleviates Hepatic Steatosis in Mouse Model","volume":"30","author":"Sun","year":"2020","journal-title":"Obes. Surg."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/cid\/ciy807","article-title":"Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade","volume":"68","author":"Sherman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"118415","DOI":"10.1016\/j.jep.2024.118415","article-title":"Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling","volume":"333","author":"Erdenebileg","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jgh.16589","article-title":"Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis","volume":"39","author":"Qi","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/liv.15914","article-title":"Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis","volume":"44","author":"Mozes","year":"2024","journal-title":"Liver Int."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kong, L.Z., Chandimali, N., Han, Y.H., Lee, D.H., Kim, J.S., Kim, S.U., Kim, T.D., Jeong, D.K., Sun, H.N., and Lee, D.S. (2019). Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112712"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"100220","DOI":"10.1016\/j.jhepr.2020.100220","article-title":"Gut dysbiosis as a driver in alcohol-induced liver injury","volume":"3","author":"Fairfield","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"101115","DOI":"10.1016\/j.gendis.2023.101115","article-title":"Mitochondrial dysfunction: A promising therapeutic target for liver diseases","volume":"11","author":"Chen","year":"2024","journal-title":"Genes. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.7150\/ijbs.49535","article-title":"Emerging Roles of SIRT1 in Alcoholic Liver Disease","volume":"16","author":"Ren","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1189\/jlb.3AB1214-590R","article-title":"Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease","volume":"98","author":"Petrasek","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Mainz, R.E., Albers, S., Haque, M., Sonntag, R., Treichel, N.S., Clavel, T., Latz, E., Schneider, K.M., Trautwein, C., and Otto, T. (2022). NLRP6 Inflammasome Modulates Disease Progression in a Chronic-Plus-Binge Mouse Model of Alcoholic Liver Disease. Cells, 11.","DOI":"10.3390\/cells11020182"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/TP.0b013e318259d38e","article-title":"Endoplasmic reticulum stress modulates liver inflammatory immune response in the pathogenesis of liver ischemia and reperfusion injury","volume":"94","author":"Liu","year":"2012","journal-title":"Transplantation"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","article-title":"CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease","volume":"58","author":"Leung","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/gutjnl-2017-315123","article-title":"Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression","volume":"68","author":"Heo","year":"2019","journal-title":"Gut"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.28680","article-title":"Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease","volume":"64","author":"Bukong","year":"2016","journal-title":"Hepatology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jhep.2015.06.013","article-title":"Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice","volume":"63","author":"Petrasek","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Brahadeeswaran, S., Dasgupta, T., Manickam, V., Saraswathi, V., and Tamizhselvi, R. (2023). NLRP3: A new therapeutic target in alcoholic liver disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1215333"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/alcalc\/agab060","article-title":"The Role of Micronutrients in the Pathogenesis of Alcohol-Related Liver Disease","volume":"57","author":"Nicoll","year":"2022","journal-title":"Alcohol. Alcohol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Hyun, J.Y., Kim, S.K., Yoon, S.J., Lee, S.B., Jeong, J.J., Gupta, H., Sharma, S.P., Oh, K.K., Won, S.M., and Kwon, G.H. (2022). Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158749"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"110","DOI":"10.55519\/JAMC-01-11171","article-title":"Association Of Fibrotic Changes In Liver On Fibro-Scan With Viral Load And Duration Of Hepatitis C Infection -A Pilot Study","volume":"35","author":"Arshad","year":"2023","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Liou, J.W., Mani, H., and Yen, J.H. (2022). Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073897"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"111556","DOI":"10.1016\/j.fct.2020.111556","article-title":"The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix","volume":"143","author":"Matsuda","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jvh.13777","article-title":"Hepatitis delta virus: Disease assessment and stratification","volume":"30","author":"Koffas","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5144\/0256-4947.2022.89","article-title":"Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals","volume":"42","author":"Alswat","year":"2022","journal-title":"Ann. Saudi Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4961919","DOI":"10.1155\/2021\/4961919","article-title":"Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients","volume":"2021","author":"Zakareya","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Cardoso, A.C., Figueiredo-Mendes, C., Villela-Nogueira, C.A., and Marcellin, P. (2022). Staging Fibrosis in Chronic Viral Hepatitis. Viruses, 14.","DOI":"10.3390\/v14040660"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3748\/wjg.v26.i7.725","article-title":"Pre-hepatectomy type IV collagen 7S predicts post-hepatectomy liver failure and recovery","volume":"26","author":"Ishii","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/jvh.13593","article-title":"Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome","volume":"28","author":"Ball","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_162","first-page":"4320","article-title":"AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes","volume":"130","author":"Dehnad","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.3748\/wjg.v27.i24.3556","article-title":"Current impact of viral hepatitis on liver cancer development: The challenge remains","volume":"27","author":"Debes","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41419-023-06043-0","article-title":"NPM promotes hepatotoxin-induced fibrosis by inhibiting ROS-induced apoptosis of hepatic stellate cells and upregulating lncMIAT-induced TGF-beta2","volume":"14","author":"Ding","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10753-021-01571-3","article-title":"Simultaneous Modulation of NLRP3 Inflammasome and Nrf2\/ARE Pathway Rescues Thioacetamide-Induced Hepatic Damage in Mice: Role of Oxidative Stress and Inflammation","volume":"45","author":"Dwivedi","year":"2022","journal-title":"Inflammation"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"152840","DOI":"10.1016\/j.tox.2021.152840","article-title":"Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms","volume":"458","author":"Ezhilarasan","year":"2021","journal-title":"Toxicology"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Liu, X., Liu, R., and Wang, Y. (2024). Indole-3-carboxaldehyde alleviates acetaminophen-induced liver injury via inhibition of oxidative stress and apoptosis. Biochem. Biophys. Res. Commun., 710.","DOI":"10.1016\/j.bbrc.2024.149880"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"155142","DOI":"10.1016\/j.phymed.2023.155142","article-title":"Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: A metabolic mechanism perspective","volume":"122","author":"Rani","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2174\/0113894501250057231102061624","article-title":"Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases","volume":"24","author":"Zhang","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Sirbe, C., Simu, G., Szabo, I., Grama, A., and Pop, T.L. (2021). Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413578"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Park, J.W., Kim, J.H., Kim, S.E., Jung, J.H., Jang, M.K., Park, S.H., Lee, M.S., Kim, H.S., Suk, K.T., and Kim, D.J. (2022). Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061288"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/modpathol.3800684","article-title":"Autoimmune liver disease: Overlap and outliers","volume":"20","author":"Washington","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/2050640619872408","article-title":"Clinical management of autoimmune hepatitis","volume":"7","author":"Pape","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s13287-021-02464-w","article-title":"Stem cell therapies for autoimmune hepatitis","volume":"12","author":"Lotfy","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Czaja, A.J. (2022). Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.921765"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Caddeo, A., and Romeo, S. (2024). Precision medicine and nucleotide-based therapeutics to treat MASH. Clin. Mol. Hepatol.","DOI":"10.3350\/cmh.2024.0438"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Carpi, S., Daniele, S., de Almeida, J.F.M., and Gabbia, D. (2024). Recent Advances in miRNA-Based Therapy for MASLD\/MASH and MASH-Associated HCC. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212229"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Targher, G., Mantovani, A., Byrne, C.D., and Tilg, H. (2024). Recent advances in incretin-based therapy for MASLD: From single to dual or triple incretin receptor agonists. Gut.","DOI":"10.1136\/gutjnl-2024-334023"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Do, A., Zahrawi, F., and Mehal, W.Z. (2024). Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat. Rev. Drug Discov.","DOI":"10.1038\/s41573-024-01084-2"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Liu, Y.J., Kimura, M., Li, X., Sulc, J., Wang, Q., Rodr\u00edguez-L\u00f3pez, S., Scantlebery, A.M.L., Strotjohann, K., Gallart-Ayala, H., and Vijayakumar, A. (2024). ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD\/MASH. J. Hepatol.","DOI":"10.1016\/j.jhep.2024.08.009"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Powell, E.E. (2024). A new treatment and updated clinical practice guidelines for MASLD. Nat. Rev. Gastroenterol. Hepatol.","DOI":"10.1038\/s41575-024-01014-y"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s40265-023-01939-9","article-title":"Alcohol-Associated Liver Disease: Evolving Concepts and Treatments","volume":"83","author":"Prince","year":"2023","journal-title":"Drugs"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"96","DOI":"10.18773\/austprescr.2021.015","article-title":"Managing medicines in alcohol-associated liver disease: A practical review","volume":"44","author":"Johnson","year":"2021","journal-title":"Aust. Prescr."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG Clinical Guideline: Alcohol-Associated Liver Disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.3748\/wjg.v27.i47.8081","article-title":"Present and future management of viral hepatitis","volume":"27","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2015). RUCAM in Drug and Herb Induced Liver Injury: The Update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management","volume":"97","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1503\/cmaj.202026","article-title":"Drug-induced liver injury","volume":"193","author":"Kumachev","year":"2021","journal-title":"CMAJ"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Panel","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"Costaguta","year":"2013","journal-title":"Pediatrics"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/MEG.0000000000001367","article-title":"Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: A meta-analysis","volume":"31","author":"Yu","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e070201","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","article-title":"The use of budesonide in the treatment of autoimmune hepatitis in Canada","volume":"22","author":"Zandieh","year":"2008","journal-title":"Can. J. Gastroenterol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Wang, Z.Y., Keogh, A., Waldt, A., Cuttat, R., Neri, M., Zhu, S., Schuierer, S., Ruchti, A., Crochemore, C., and Knehr, J. (2021). Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-98806-y"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Ye, B., Yu, M., Yue, M., Yin, M., Zhang, C., Wang, Q., Ding, X., Shen, W., and Zhao, Z. (2023). Role of PDLIM1 in hepatic stellate cell activation and liver fibrosis progression. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-38144-3"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/labinvest.2009.77","article-title":"Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787\/ZK22258","volume":"89","author":"Liu","year":"2009","journal-title":"Lab. Investig."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Zhang, D., Zhang, Y., and Sun, B. (2022). The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012572"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2468-1253(18)30232-2","article-title":"Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension","volume":"3","author":"Qi","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14218\/JCTH.2018.00006","article-title":"Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review","volume":"6","author":"Bellan","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Yoon, Y., Gong, S.C., Kim, M.Y., Baik, S.K., Hong, J.E., Rhee, K.J., Ryu, H., and Eom, Y.W. (2023). Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages. Cells, 12.","DOI":"10.3390\/cells12212514"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"20417314241268344","DOI":"10.1177\/20417314241268344","article-title":"Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues","volume":"15","author":"Ma","year":"2024","journal-title":"J. Tissue Eng."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1038\/s41467-020-17161-0","article-title":"Mechano-modulatory synthetic niches for liver organoid derivation","volume":"11","author":"Sorrentino","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Pantano, L., Agyapong, G., Shen, Y., Zhuo, Z., Fernandez-Albert, F., Rust, W., Knebel, D., Hill, J., Boustany-Kari, C.M., and Doerner, J.F. (2021). Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-96966-5"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-5-1","article-title":"Genomics and proteomics in liver fibrosis and cirrhosis","volume":"5","author":"Hannivoort","year":"2012","journal-title":"Fibrogenesis Tissue Repair."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:20Z","timestamp":1760115380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":210,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121724"],"URL":"https:\/\/doi.org\/10.3390\/ph17121724","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}